FDA Corrects Withdrawal of Propoxyphene Drug Approval, Includes Xanodyne Pharmaceuticals

Summary

The FDA is correcting a notice that withdrew approval of 8 new drug applications and 46 abbreviated new drug applications for prescription pain medications containing propoxyphene, including a mistake that left Xanodyne Pharmaceuticals' NDA 017507 still approved